The Impact of Matching Vaccine Strains and Post-SARS Public Health Efforts on Reducing Influenza-Associated Mortality among the Elderly by Chan, Ta-Chien et al.
The Impact of Matching Vaccine Strains and Post-SARS
Public Health Efforts on Reducing Influenza-Associated
Mortality among the Elderly
Ta-Chien Chan
1,2, Chuhsing Kate Hsiao
1,3, Chang-Chun Lee
1, Po-Huang Chiang
2, Chuan-Liang Kao
1,4,
Chung-Ming Liu
5,6, Chwan-Chuen King
1,3*
1Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan, 2Division of Health Policy Research, Institute of Population Health
Science, National Health Research Institutes, Zhunan, Taiwan, 3Department of Public Health, College of Public Health, National Taiwan University, Taipei, Taiwan,
4Department of Clinical Laboratory Science and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan, 5Global Change Research
Center, National Taiwan University, Taipei, Taiwan, 6Department of Atmospheric Sciences, College of Science, National Taiwan University, Taipei, Taiwan
Abstract
Public health administrators do not have effective models to predict excess influenza-associated mortality and monitor viral
changes associated with it. This study evaluated the effect of matching/mismatching vaccine strains, type/subtype pattern
changes in Taiwan’s influenza viruses, and the impact of post-SARS (severe acute respiratory syndrome) public health efforts
on excess influenza-associated mortalities among the elderly. A negative binomial model was developed to estimate
Taiwan’s monthly influenza-associated mortality among the elderly. We calculated three winter and annual excess influenza-
associated mortalities [pneumonia and influenza (P&I), respiratory and circulatory, and all-cause] from the 1999–2000
through the 2006–2007 influenza seasons. Obtaining influenza virus sequences from the months/years in which death from
P&I was excessive, we investigated molecular variation in vaccine-mismatched influenza viruses by comparing
hemagglutinin 1 (HA1) of the circulating and vaccine strains. We found that the higher the isolation rate of A (H3N2)
and vaccine-mismatched influenza viruses, the greater the monthly P&I mortality. However, this significant positive
association became negative for higher matching of A (H3N2) and public health efforts with post-SARS effect. Mean excess
P&I mortality for winters was significantly higher before 2003 than after that year [mean 6 S.D.: 1.4461.35 vs. 0.3561.13,
p=0.04]. Further analysis revealed that vaccine-matched circulating influenza A viruses were significantly associated with
lower excess P&I mortality during post-SARS winters (i.e., 2005–2007) than during pre-SARS winters [0.0360.06 vs.
1.5761.27, p=0.01]. Stratification of these vaccine-matching and post-SARS effect showed substantial trends toward lower
elderly excess P&I mortalities in winters with either mismatching vaccines during the post-SARS period or matching vaccines
during the pre-SARS period. Importantly, all three excess mortalities were at their highest in May, 2003, when inter-hospital
nosocomial infections were peaking. Furthermore, vaccine-mismatched H3N2 viruses circulating in the years with high
excess P&I mortality exhibited both a lower amino acid identity percentage of HA1 between vaccine and circulating strains
and a higher numbers of variations at epitope B. Our model can help future decision makers to estimate excess P&I
mortality effectively, select and test virus strains for antigenic variation, and evaluate public health strategy effectiveness.
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Introduction
Increased influenza vaccination coverage for the elderly, one of
the highest risk groups for influenza-related deaths [1], has
prevented influenza-related complications and deaths, based on 64
studies from 1964 to 2006 [2]. In Taiwan, elderly populations
(aged $65 years) have received free influenza vaccination since
1998. Vaccine coverage rates have increased from 9.9% in 1998 to
49.1% in 2007. Despite similar expansions in coverage, pneumo-
nia and influenza (P&I) mortality among the elderly have
continued to rise in Italy [3] and the United States [4,5]. Such
findings contribute to the current international debate on the
influenza vaccine’s effectiveness in preventing elderly influenza-
associated deaths. To examine this issue, we investigated the
impact of potential vaccination mismatches with co-circulating
viral strains of influenza virus types/subtypes, and public health
efforts after the 2003 outbreak of SARS on vaccination
effectiveness in subtropical regions like Taiwan.
Routine virological surveillance has been crucial for early
detection of influenza viral changes [6]. Understanding epidemi-
ological pattern changes of influenza in Taiwan, located
geographically close to several past influenza pandemic epicenters
in China and Southeast Asia, has larger implications for global
virological surveillance. Taiwan’s dominant circulating A(H3N2),
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11317A(H1N1), and B wild-type influenza virus strains appeared about
one to two years earlier than selected vaccine strains recommend-
ed by World Health Organization (WHO) for the northern
hemisphere, implying that Taiwan has the potential to play a key
role in early pandemic and epidemic detection and control [7,8].
The aims of this study were: (1) to evaluate the effectiveness of
matching or mismatching influenza vaccine strains on influenza-
associated mortality, (2) to assess whether public health improve-
ments during the post-SARS period might have decreased elderly
mortality, and (3) to investigate molecular variation among
vaccine-mismatched influenza viruses that may be associated with
increased excess influenza-associated mortality.
Methods
Data Sources and Definition of Influenza Seasons
Data was collected on Taiwan’s annual and monthly influenza-
associated mortality rates for the elderly population, monthly
meteorological conditions (obtained from Taiwan’s Central
Weather Bureau), annual influenza vaccine strains (collected from
the WHO) [9], dominant types/subtypes of influenza viruses for
winter epidemic seasons, and monthly influenza isolation rates
[compiled from the Centers for Disease Control in Taiwan
(Taiwan-CDC)] for the 1999–2000 through 2006–2007 influenza
seasons. Rates of both winter and annual influenza-associated
excess mortality among the elderly were calculated. Winters
periods were designated as December 1
st to February 28
th of the
following year. Annual periods were marked as beginning on
October 1
st and concluding on September 30th of the following
year. The elderly population was calculated as the average of two
mid-years’ elderly population (acquired from the Census database
of the Ministry of the Interior). Monthly isolation rates of influenza
virus types/subtypes for each studied year were obtained from the
Virological Surveillance Database of Contract Laboratories and
compiled by Taiwan-CDC (Figure S1) [10]. Wild-type, dominant
circulating influenza virus strains were also collected from the
Contract Laboratories, as designated by Taiwan-CDC and the
literature [8]. Comparisons between influenza vaccine strains and
Taiwan’s dominant influenza epidemic strains are summarized in
Table S1.
To better evaluate influenza’s disease burden, we used influenza-
associated mortality rates that were calculated under broad
definitions [4]. Using International Classification of Diseases, ninth
revision (ICD-9) codes and clinical data obtained from Taiwan’s
Department of Health, mortality was divided into three categories:
(1) pneumonia and influenza (P&I, ICD-9: 480–487), (2) respiratory
and circulatory (R&C, ICD-9: 390–519), and (3) all-cause deaths
(ICD-9: 000–999) with the exclusion of non-natural deaths.
Data Analyses and Statistical Tests
We developed a negative binomial regression model and added
two variables of vaccine match/mismatch and pre/post-SARS
effect for multivariate analyses with a modification of a
Thompson-like model [4], because of dispersed distributions of the
three influenza-associated mortality rates (variance/mean .20).
Explanatory variables for the above three outcome measures
include monthly meteorological parameters (monthly means of
temperature and humidity), annual periodic cycle (i.e., sine/cosine
function of seasonal periodicity), monthly virus isolation rates for
different subtypes/types of influenza viruses [A (H3N2) or A
(H1N1) or B], matching status of different vaccine strains for each
subtype/type in each of the studied years, post-SARS effect, and
linear temporal monthly trends. Matching status for each subtype/
type of influenza viruses was defined as the consistency between
the nomenclature of the vaccine strain and the nomenclature of
that season’s dominant wild-type strain in Taiwan. If no wild-type
subtype was isolated for a certain year, the status of the flu vaccine
was thus coded as ‘‘matching’’ for that subtype/type and year. To
assess whether the public health effort after the 2003 unique
outbreak of SARS in Taiwan might also play a role in mortality,
the indicator variable ‘‘post-SARS effect’’ was applied to the
period beginning October 2003 (the first month of the 2003
influenza season) till after the conclusion of the outbreak in June
2003.
Model selection was based on Akaike’s information criterion
(AIC) and likelihood ratio test [11]. When modeling P&I
mortality, both mean temperature and relative humidity were
found to be without statistical significance and were thus excluded
from the full model (Table 1). The model was implemented by
SAS (version 9.1; SAS Institute Inc, Cary, NC). The final model
for ‘‘influenza-associated deaths’’ was devised as follows:
Log(E(Y))~azb0zb1|½A(H1N1) zb2|½A(H3N2) 
zb3|½B zb4|½A(H1N1) matching 
zb5|½A(H3N2) matching zb6|½Bmatching 
zb7|½post   SARS zb8|½time 
zb9|½cos(2p time=12) zb10|½sin(2p time=12) 
zb11|½meanTemp zb12|½meanRH 
Winter and annual influenza-associated excess elderly
mortalities
To evaluate the impact of influenza vaccination and/or post-
SARS effect on influenza-associated elderly mortalities, we listed
both variables in Table 2. Excess mortality (95% confidence
interval) was calculated for each winter and year. These excess
deaths were assessed by calculating the difference between
observed data and expected baselines that were derived from the
negative binomial model (Figure S2). When we modeled vaccine-
matching status and post-SARS effect, we coded data as ‘‘1’s’’ or
‘‘0’s’’ depending on the actual data for each year. ‘‘Post-SARS’’
was defined as all months after October 2003. After calculating
residual deaths for each month, we replaced negative residuals
(e.g. observed values less than the expected value) with zero and
summed up excess deaths for each influenza season. Winter (or
annual) excess mortality rates were calculated based on each
winter’s (or annual) total excess deaths divided by mid-year mean
populations. In other words, we assessed temporal differences
between each winter’s monthly observed influenza-associated
deaths and monthly expected value [obtained from our multivar-
iate modeled deaths (baseline)], and then divided these monthly
differences by the mid-year mean population for two years to
calculate the actual excess mortality rate in each winter for
statistical comparison among the three time periods (prior to
SARS, during SARS, and post-SARS) (Table 2, Table S2). The
mean values for each winter’s excess mortality before and after
SARS were evaluated by independent T-test.
Phylogenetic Analysis of HA1 in Taiwanese H3N2 Viruses
To better understand why 2001–2002 exhibited the highest
winter and annual excess P&I mortality rates, HA1 sequences of
the 2002 epidemic influenza virus A (H3N2) Fujian strain (A/
Fujian/411/2002 (H3N2)), vaccine strains (red squared symbol)
from 1999 to 2007, and other Taiwanese H3N2 isolates (circular
Vaccine & Influenza Mortality
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Center for Biotechnology Information (NCBI) for genetic
comparison. We then constructed a phylogenetic tree of HA1
amino acids among Taiwanese A (H3N2) virus strains using the
Neighbor-Joining method. This tree was bootstrapped 1,000 times
with Mega 4.0 software [12].
Amino Acid Identity and Qualitative Analysis of Epitopes
of HA1 of Influenza Vaccine-mismatched Circulating
Versus Vaccine A (H3N2) Virus Strains
Percentages of amino acid sequence identity in the HA1 between
dominant wild-type circulating and vaccine strains were calculated
for vaccine-mismatched influenza A(H3N2) viruses isolated from
months and years (1999–2000, 2003–2004, and 2004–2005) with
high annual/monthly influenza-associated excess P&I mortality.
The numbers and percentages of amino acid difference at specific
epitope locations of HA1 that have been documented in literature
[13] were further analyzed for vaccine-mismatched influenza A
(H3N2) viruses isolated from these three years.
Results
Temporal Patterns of Three Influenza-Associated
Mortality Rates
Temporal patterns of influenza-associated mortality rates
indicate that Taiwan’s elderly P&I mortalities have been
increasing since the beginning of the 2001–2002 influenza season
despite significant increases in vaccine coverage (Figure S3A). As
described in Figure 1, the mean P&I mortality rate, 12.97 per
100,000 prior to September 2001, significantly surged to 18.17 per
100,000 (p-value ,0.001) after October 2001 (after the open travel
policy with China commenced on January 1, 2001) [14]. These
increasing patterns were consistent throughout the study period
among the three oldest age groups (65–74, 75–84, and 85+)
(Figure S3B). In addition to this temporal pattern, seasonal cycles
(cosine and sine function in Table 1) were also found to be
significant (p,0.01) for all three influenza-associated mortality
rates (except for the cosine function for R&C). Furthermore, the
corresponding coefficients in Table 1’s model demonstrate the
considerable reduction in elderly P&I mortality in years with either
matching vaccines or post-SARS effect.
Virological Surveillance and Mismatched Vaccine Strains
Temporalpatternsofmonthlyisolationratesforhumaninfluenza
viruses in Taiwan are displayed in Figure S1. During the study
period, A (H3N2) and B were the dominant type/subtypes of
influenza viruses. Influenza A (H1N1) was dominant in the 2001–
2002 and 2005–2006 seasons, based on information from Taiwan-
CDC and NCBI gene bank. Additionally, A (H3N2) was dominant
during all summer flu seasons after the 2003 SARS outbreak.
Regarding to vaccine matching rate, A (H1N1) was the most
frequently matched subtype (87.5%, 7/8) in eight epidemic
seasons. A (H3N2) had the second highest (62.5%, 5/8) and B
had the worst (50%, 4/8).
Influenza-Associated Mortality Models
Using multivariate negative binomial regression models, we
found that four significant variables – the monthly isolation rate of
Table 1. Estimated coefficients ( “ b), standard errors (SE) and p-values (p) of three fitted negative binomial models for influenza-
associated deaths: (1) pneumonia and influenza (P&I), (2) respiratory and circulatory, and (3) all-cause in Taiwan, from October 1999
to September 2007, respectively.
(1) P&I Deaths (2) Respiratory and Circulatory Deaths (3) All-Cause Deaths
Parameters “ b SE p “ b SE p “ b SE p
Intercept, b0 28.996 0.061 ,.0001* 25.326 0.214 ,.0001* 24.628 0.158 ,.0001*
A/H1N1 Isolation Rate, b1 0.569 0.393 0.147 20.183 0.165 0.268 20.135 0.122 0.271
A/H3N2 Isolation Rate, b2 0.860 0.335 0.010* 0.326 0.139 0.019* 0.250 0.103 0.015*
Flu B Isolation Rate, b3 20.133 0.208 0.522 20.072 0.088 0.408 20.025 0.065 0.701
A/H1N1 Vaccine Strain
Matching, b4
0.192 0.111 0.085 20.058 0.045 0.202 20.028 0.034 0.401
A/H3N2 Vaccine Strain
Matching, b5
20.244 0.060 ,.0001* 20.002 0.025 0.923 20.001 0.018 0.949
Flu B Vaccine Strain
Matching, b6
20.030 0.058 0.612 20.050 0.024 0.038* 20.027 0.018 0.131
Post-SARS Effect, b7 20.380 0.105 0.000* 20.067 0.043 0.116 20.047 0.032 0.139
Linear Temporal Trends, b8 0.009 0.002 ,.0001* 0.001 0.001 0.364 0.001 0.001 0.474
Cosine, b9 20.081 0.020 ,.0001* 0.033 0.025 0.183 0.056 0.018 0.002*
Sine, b10 0.087 0.021 ,.0001* 20.104 0.030 0.001* 20.104 0.022 ,.0001*
Mean Temperature, b11 NA 20.041 0.007 ,.0001* 20.035 0.005 ,.0001*
Relative Humidity, b12 NA 20.005 0.002 0.017* 20.004 0.002 0.011*
*Statistically significant (p,0.05).
NA, Excluded by the Akaike Information Criterion (AIC) and likelihood ratio test.
a is an offset term equal to the log of elderly mid-year population size for each year.
b4,b6, coded as ‘‘1’’ if the vaccine of that subtype/type had been matched and ‘‘0’’ for others.
b7 (Post-SARS Effect), coded as ‘‘1’’ for the months after October, 2003 and ‘‘0’’ for others.
b8, coded 1 through 96 from October, 1999 to September, 2007. If no wild-type strain in a subtype was isolated for a certain year, the status of the flu vaccine was thus
coded as ‘‘matching’’ for that subtype and year.
doi:10.1371/journal.pone.0011317.t001
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temporal trends, and sine function – were all positively correlated
with annual P&I deaths (p,0.05, Table 1). In contrast, post-SARS
effect and cosine function were negatively correlated with annual
P&I mortality (p,0.05). Influenza A (H3N2)’s monthly isolation
rate and sine function, as well as vaccine mismatch for influenza B,
were positively correlated with R&C deaths (p,0.05). Mean
temperature and relative humidity were both negatively correlated
with R&C deaths (p,0.05). Values for observed and estimated
deaths were proximate for all three influenza-associated mortality
models (as illustrated in Figure S2).
Excess Mortality, Post-SARS Effect, and Vaccine Match/
Mismatch
1. 2003 SARS Outbreak. During Taiwan’s SARS epidemic
(March–June 2003), excess P&I mortality rates (11.0 per 100,000)
were 2–5 times higher than rates for the same months in prior
years and about 8 times higher than rates for the four months
preceding the outbreak (Table S2). In May 2003, when inter-
hospital nosocomial infection was the most severe, the three
influenza-associated excess mortality rates of P&I (22.09 per
100,000), R&C, and all-cause ranked the highest throughout the
studied months. After June 2003, excess P&I mortalities in July
and August declined dramatically to 0 per 100,000 (Figure S2).
2. Pre- and Post-SARS Periods. The mean of excess
influenza-associated mortalities of P&I and R&C for winters
before 2003 was significantly higher than after 2003 (i.e. post-
SARS period) [P&I excess mortality: mean 6 standard deviation
(S.D.): 1.4461.35 vs. 0.3561.13, p=0.04; R&C excess mortality:
5.0/100,000 vs. 1.7/100,000, p=0.04].
3. Stratification Analysis. Totally, four of the eight studied
years showed increased winter excess influenza-associated
mortalities ("3/100,000) plus one higher excess mortality in
March, 2005 (5.28/100,000), and five of them had vaccine-
mismatches. Of the latter five, three occurred in the pre-SARS
period (1999–2000, 2000–2001, and 2001–2002) and the
remaining two happened in the post-SARS period (2003–2004
and 2004–2005). To examine the winter seasons’ excess mortality
in those years with vaccine-matched versus vaccine-mismatched
strains before and after SARS, we first reviewed the data on
vaccine-matches or not during the pre-SARS years only (e.g.
without effect of SARS). Then, we focused on vaccine-mismatches
Table 2. Annual and winter excess mortality rates of influenza-associated deaths (per 100,000) among the elderly ("65 years).
Winter Vaccine matching status & Post-SARS impact Annual excess mortality Winter excess mortality
(By Years) (95% CI) (95% CI)
A. Pneumonia and Influenza Excess Mortality
1999–2000 Mismatched H1 & H3+without post-SARS 8.1 (3.5–14.3) 3.0 (2.0–4.0)
2000–01 Mismatched B+without post-SARS 6.9 (3.1–11.5) 6.2 (3.1–9.2)
2001–02 Mismatched B+without post-SARS 14.4 (6.5–25.5) 6.5 (2.8–10.9)
2002–03 Matched H3 & H1& B+without post-SARS 12.6 (6.1–21.8) 1.4 (0.0–3.6)
2003–04 Mismatched H3 & B+post-SARS 9.1 (3.6–20.8) 4.0 (1.9–7.1)
2004–05 Mismatched H3 & B+post-SARS 10.0 (5.7–17.6) 0.2 (0.0–2.6)
2005–06 Matched H3 & H1 & B+post-SARS 8.7 (4.8–20.9) 0.2 (0.0–2.7)
2006–07 Matched H3 & H1 & B+post-SARS 4.4 (1.9–14.5) 0.0 (0.0–3.5)
B. Respiratory and Circulatory
1999–2000 Mismatched H1 & H3+without post-SARS 49.6 (21.4–76.9) 23.4 (8.1–38.1)
2000–01 Mismatched B+without post-SARS 21.2 (5.3–44.7) 16.5 (5.3–28.2)
2001–02 Mismatched B+without post-SARS 36.0 (15.8–67.6) 20.4 (9.0–35.2)
2002–03 Matched H3 & H1& B+without post-SARS 28.3 (15.9–60.4) 0.0 (0.0–8.7)
2003–04 Mismatched H3 & B+post-SARS 21.3 (6.0–51.1) 7.4 (1.6–20.1)
2004–05 Mismatched H3 & B+post-SARS 30.4 (6.6–64.0) 2.8 (0.0–10.8)
2005–06 Matched H3 & H1 & B+post-SARS 33.1 (13.7–65.5) 9.0 (2.5–20.1)
2006–07 Matched H3 & H1 & B+post-SARS 17.2 (8.7–50.9) 1.1 (0.0–13.9)
C. All-Cause
1999–2000 Mismatched H1 & H3+without post-SARS 75.0 (23.0–133.7) 33.6 (6.0–60.6)
2000–01 Mismatched B+without post-SARS 43.6 (14.8–103.3) 29.5 (12.1–51.1)
2001–02 Mismatched B+without post-SARS 63.3 (24.8–114.5) 31.6 (11.3–51.8)
2002–03 Matched H3 & H1& B+without post-SARS 61.0 (31.9–118.7) 0.9 (0.0–18.2)
2003–04 Mismatched H3 & B+post-SARS 30.7 (5.6–96.8) 14.9 (0.0–44.2)
2004–05 Mismatched H3 & B+post-SARS 69.6 (27.5–135.7) 5.8 (0.0–16.7)
2005–06 Matched H3 & H1 & B+post-SARS 59.2 (24.8–123.7) 22.4 (7.2–43.2)
2006–07 Matched H3 & H1 & B+post-SARS 45.8 (17.0–119.7) 3.9 (0.0–31.2)
#Annual: from October to the following September.
Winter: from December to the following February.
doi:10.1371/journal.pone.0011317.t002
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of vaccine-matches).
In 2002–2003 winter (during the ‘‘pre-SARS’’ period), well
vaccine-matched influenza strains resulted in a monthly mean of
0.45/100,000 excess P&I mortality. This was lower than vaccine-
mismatched winters before 2002 [mean 6 S.D.: 0.45/100,0006
0.78 vs. 1.77/100,00061.36, p=0.2]. In other words, mismatched
vaccine did show a trend in increased P&I mortalities in those
years without post-SARS effect. In the 2005–2006 and 2006–2007
winters (during the ‘‘post-SARS period), well vaccine-matched
influenza strains were also associated with lower excess P&I
mortalities compared to the vaccine-mismatched winters during
the ‘‘post-SARS’’ period [mean 6 S.D.: 0.03/100,0006
0.06 in 2005–07’s winter months vs. 0.68/100,00061.59 in those
of vaccine-mismatched winters’ months after 2003, p=0.33], and
the winter of 2002–2003 (i.e. 0.45/100,000, p=0.4).
Comparing vaccine-mismatches in pre- and post-SARS winters,
we found another trend: the excess P&I mortality mean in
influenza vaccine-mismatched winters in pre-SARS was much
higher than the mean in post-SARS winters (1.861.4 vs. 0.761.6,
p=0.2). In other words, post-SARS years showed a trend toward
reduced influenza-associated mortality while vaccines were
mismatched. Similar trends appeared that well influenza A (i.e.
H1N1 and H3N2) vaccine-matches during post-SARS winters (i.e.
2005–2007) showed significantly lower excess P&I mortality than
vaccine-matched influenza A viruses during pre-SARS winters
[mean 6 S.D.: 0.0360.06 vs. 1.5761.27, p=0.01]. Furthermore,
2005–2006 and 2006–2007 had the two lowest P&I excess
mortalities during the post-SARS period.
In summary, stratification of these two variables showed
substantial trends toward lower excess P&I mortality during: (1)
influenza vaccine-matched winters during the pre-SARS period
(without post-SARS effect), and (2) influenza vaccine-mismatched
winters in the post-SARS period.
HA1 Amino Acid Identity Percentage, Phylogenetic
Analysis and Epitope Variation of Taiwanese H3N2
Isolates versus Vaccine H3N2 Strains
To find whether the molecular-variations of influenza viruses
might correlate with annual influenza-associated excess mortalities
during 1999–2000, 2003–2004, and 2004–2005 (Table 2), we
investigated the percentage of amino acid identity between
circulating and vaccine strains, their phylogenetic relatedness,
and amino acid differences at specific epitope locations in the HA1
of Taiwanese influenza A (H3N2) versus vaccine A (H3N2) strains.
After examining the amino acid identity of vaccines and their
corresponding circulated viral strains, we found that the
mismatched A (H3N2) virus in 1999–2000 had a HA1 amino
acid identity percentage of 96.4%. This was a higher identity
percentage than in 2003–2004 (93.2%) but a lower identity
percentage than in 2004–05 (97.1%) (Table 3). These quantitative
differences correlate with the P&I excess mortality observed in
1999–2000’s winter season (3.0/100,000), which was lower than in
2003–2004’s winter season (4.0/100,000) but higher than in 2004–
2005’s winter season [0.2/100,000 (Table 2)]. The high winter and
annual excess P&I mortalities in 2001–2002, before the 2003
SARS outbreak, can be explained in part by the 90.4% identity
percentage of vaccine strain B/Sichuan/379/99 to the B/Hong
Kong/330/2001 strain. This time period also began the
emergence of the A (H3N2) Fujian strain in the region. After
the 2003 SARS outbreak, winter excess mortality in 2003–2004
ranked the highest due to low identity (93.2%) of the vaccine strain
[A/Moscow/10/99-like (H3N2)] to the existing A/Fujian/411/
2002 (H3N2) virus. In March 2005, when excess influenza-
associated P&I mortality peaked (5.28 per 100,000) during
October 1
st 2004–September 30
th 2005, the isolated influenza B
strains of Victoria lineage (B/Malaysia/2506/2004) [15] were
shown to be mismatched (89.9% amino acid identity) with vaccine
strains of Yamagata lineage (B/Shanghai/361/2002-like) [16,17].
Figure 1. Monthly influenza-associated mortality rates for the 1999–2000 through 2006–2007 influenza seasons in Taiwan. Left Y-
axis represents respiratory and circulatory mortality and all-cause (natural deaths) mortality. Right Y-axis represents pneumonia and influenza
mortality. Panel A represents prior and during SARS period from October 1999 to September 2003. Panel B represents post-SARS period from
October 2003 to September 2007. Three linear regression lines for the three corresponding influenza-associated mortality rates were drawn as dotted
lines: (1) pneumonia and influenza mortality [red line], (2) respiratory and circulatory mortality [green line], and (3) all-cause (natural deaths) mortality
[blue line].
doi:10.1371/journal.pone.0011317.g001
Table 3. Amino acid sequence identities between vaccine strains and dominant wild-type strains of A (H3N2) in Taiwan from 1999
through 2007.
Amino Acid Sequence Identity Percentage (%)
Vaccine Strains
Dominant Strains
A/Sydney/5/97-like
(H3N2)
A/Moscow/10/99-like
(H3N2)
A/Fujian/411/2002-like
(H3N2)
A/Wisconsin/67/05-like
(H3N2)
A/Sydney/05/97 (H3N2) 0.996 0.96* 0.932 0.911
A/Moscow/10/99 (H3N2) 0.975 0.975 0.939 0.925
A/Fujian/411/2002 (H3N2) 0.935 0.932** 1 0.957
A/California/7/2004 (H3N2) 0.914 0.911 0.971*** 0.971
A/Wisconsin/67/05 (H3N2) 0.911 0.903 0.964 0.985
*The vaccine was mismatched in the 1999–2000 season.
**A/Fujian/411/2002 was not a dominant strain during 2001–2002’s season. The Vaccine was mismatched during the 2003–2004 season.
***The Vaccine was mismatched in the 2004–2005 season.
doi:10.1371/journal.pone.0011317.t003
Vaccine & Influenza Mortality
PLoS ONE | www.plosone.org 6 June 2010 | Volume 5 | Issue 6 | e11317High excess mortality was therefore observed in March of that
year rather than in the winter season during December 1
st 2004–
February 28 2005.
Phylogenetic analysis of amino acids in the HA1 of Taiwanese A
(H3N2) viruses from 1996 to 2008 (Figure S4) displays A (H3N2)
isolates obtained from the same year as clusters. The A (H3N2)
Fujian strain, firstly isolated from China in August of 2002 and
circulated dominantly in 2003 in Taiwan with notably high excess
P&I mortality, was found to be phylogenetically distinct from other
A(H3N2) strains.
To investigate whether more variation of HA1 epitopes between
vaccines and dominant circulating strains might lead to higher
excess mortality, we compared Taiwan’s dominant circulating
H3N2 strains with the vaccine H3N2 strains used during 1999–
2000, 2003–2004, and 2004–2005 (Table S4, Figure S4). During
the 1999–2000 flu season, A/Sydney/05/97(H3N2) and A/
Moscow/10/99(H3N2) were the dominant circulating strains
affecting Taiwan while A/Sydney/05/97-like was the vaccine
strain and provided inadequate protection against A/Moscow/
10/99. As shown in Table S3, five variations were identified at
known epitopes [13], including two variations (Y137S, S142R) at
epitope A [17% (2/12)], two (K160R, A196T) at epitope B [13%
(2/16)], and one (R57Q) at epitope E [8% (1/13)]. No variations
were found at epitopes C (0/8) or D (0/13) (Table S4). Most
notably, we discovered one variation at the undefined epitope
(position 3, I3L) previously identified by Shih et al. [13], and three
new variations (positions of A138S, I194L, Y233H, Figure S5)
without documentation in the literature. During the 2003–2004 flu
season that followed the SARS outbreak, the dominant A/Fujian/
411/2002 (H3N2) strain [mismatched with vaccine strain A/
Moscow/10/99 (H3N2)] was phylogenetically distinct from other
H3N2 strains and exhibited high epitope B variations (9/19, 47%).
Surprisingly, nine of the 19 amino acid differences in HA occurred
at epitope B. Fewer variations were observed at other epitopes [A
(8%, 1/13), C (13%, 1/8), D (8%, 1/13), E (15%, 2/13)] (Table
S4). During the 2004–2005 flu season, the dominant A/
California/7/2004 (H3N2) strain did not match with the vaccine
A/Fujian/411/2002 (H3N2) strain. Again, the major variations
occurred mostly at epitope B (4/8, 50%). The remaining
variations included one at epitope A [1/12 (8%) at K145N], two
(V226I, S227P) at epitope D [2/13 (15%)], and one new variation
at A138S that had appeared during the 1999–2000 flu season
(Table S4). We also observed that the excess mortality in 2004–
2005’s winter was much lower than in 1999–2000. This can be
supported by higher identity percentage between vaccine and
circulating strains, and a lower number of variations at epitope B.
In 2003–2004, there were more variations (9/19) at epitope B in
circulating and vaccine-mismatched A (H3N2) strains than in the
2004–2005 influenza season. There was also a higher winter
excess P&I mortality in 2003–2004 as compared to in 2004–2005.
Discussion
This is the first study to analyze the impact of the dominant
types/subtypes of influenza viruses, the matching status of
influenza vaccine strains, and the 2003 SARS outbreak on three
influenza-associated mortality rates among the elderly in Taiwan.
The study is unprecedented in its molecular-level investigation of
vaccine-mismatched influenza viruses associated with excess
mortality. While the limitations of our data prevent us from
drawing definitive conclusions about these potential factors, we did
observe five associations that merit discussion. First, higher A
(H3N2) subtype isolation rates were associated with increased
influenza-associated mortality. Second, lower P&I mortality rates
were observed when circulating strains of influenza viruses were
vaccine-matched. Third, increased influenza P&I excess mortality
was associated with vaccine-mismatched circulating influenza
H3N2 and B viruses with fewer amino acid identities. Fourth,
influenza disease burden after the 2003 SARS outbreak (i.e. with
post-SARS effect) was significantly lower than before this SARS
outbreak. Lastly, patterns of Taiwan’s influenza types/subtypes
became more diversified after 2001 when Mini links with China
facilitated open travel exchanges [14]. Co-circulation of H3N2
subtype with H1N1 subtype or B type viruses resulted in higher
P&I mortality than any subtype/type acting alone. Our observa-
tions suggest that improvements in public education and public
health efforts (as a result of post-SARS effects and better vaccine
matching) may have contributed to a reduction in P&I mortality.
This trend would be further supported if mortality reductions
persist in the presence of adequately sustained prevention
measures. Our study suggests that the future deployment of
epidemiological measures such as virological surveillance (obtain-
ing more specimens), timely molecular analysis of viral isolates and
their accompanying vaccine strains, and identification of vaccine-
mismatched strains would support public health efforts to
minimize complications and deaths. We recommend that public
health resources be allocated to include both pharmaceutical [18]
and non-pharmaceutical interventions [19] for minimizing elderly
deaths whenever vaccine-mismatched H3N2 viruses are domi-
nant. Daily syndromic surveillance data integrated with virological
surveillance information and statistical methods for detecting
abnormal signals and trends can provide timely information for
identifying the occurrence of vaccine-mismatched or novel
influenza viruses. These efforts can jump-start prevention at the
initial phase of an epidemic, when there is a higher risk of human-
to-human transmission (e.g., increased epidemic/pandemic po-
tential of newly emerged influenza viruses). As outbreaks of
emerging infectious diseases (EID) and novel influenza viruses
continue to increase [20], we believe our results will help countries
have not affected by SARS to evaluate the effectiveness of their
preventive and/or control measures for reducing influenza disease
burdens (including vaccination programs for the current influenza
H1N1 pandemic in 2009–2010).
In addition to determining the effectiveness of vaccine strains in
a given flu season, variant epitopes on the surface of the virus may
also result in varying immunological responses. Certain epitope
variants might be less effective at stimulating the development of
B-cell humoral immunity or interfere with the ability of cytotoxic
T-lymphocytes to recognize epitopes presented by HLA class I
proteins on the surface of infected cells [21]. Analysis of data from
pre-SARS winters—before the initiation of public health inter-
vention efforts prompted by SARS—may provide more clues as to
the impact of vaccine-mismatched influenza viruses on excess
mortality. In addition, Taiwan’s vaccine-mismatched influenza
viruses appeared prior to the introduction of WHO’s recom-
mended vaccine strain [22]. Therefore, it is explainable why we
observed higher excess P&I mortality during pre-SARS vaccine-
mismatches than post-SARS. The mismatched A (H3N2) Fujian
strain which appeared in 2002 and circulated for several months
may have steadily increased the population’s herd immunity
leading up to 2004–2005. Lower influenza-associated excess
mortality during the winter of 2004–2005, particularly in
comparison to 1999–2000, may also be attributed to a higher
identity percentage between vaccine strains and circulating strains,
a lower number of variations at epitope B, the development of
herd immunity, and the post-SARS effect. These two vaccine-
mismatching examples suggest that both quantitative and
qualitative variations of amino acids, as well as the locations and
Vaccine & Influenza Mortality
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vaccine-mismatched influenza viruses. Antigenic differences thus
need to be identified efficiently by serological testing for isolated
influenza viruses with high monthly/weekly excess P&I mortality
[23]. Our results suggest that timely identification of vaccine-
mismatched circulating influenza viruses and their antigenic
variations is crucial for effective evidence-based public health
planning and preparedness.
From January 2001–October 2001, documented vaccine
effectiveness (VE) was 53% for preventing pneumonia deaths
(when B was mismatched) and 44% for preventing all-cause deaths
among the elderly in Taiwan [24]. Matched vaccines reached a
VE as high as 80% for preventing influenza among healthy adults
[25]. This VE declined to 50% when vaccines mismatched with
circulating influenza viruses. We can surmise from past data that
the VE for mismatched vaccines would be even lower for elderly
populations because of their weakened immune responses [26].
The variation of VE across different countries may be attributed to
different age distributions, variable influenza vaccination coverage
rates [27], and variation in post-SARS effects. These variations
may account for the higher overall P&I mortality and excess P&I
mortality rates observed in Italy and U.S compared to Taiwan.
The 2003 SARS outbreak posed a significant challenge to
Taiwan’s health care system but also had the potentially beneficial
effect of educating the public about the need for seeking health care
earlier [28] and protective behaviors [29,30]. Public education
measures and behavioral changes prompted by the SARS outbreak
may have contributed to the ensuing decline in excess P&I mortality
in Taiwan and other SARS-affected countries/areas [29,31].
Although our observation periods were not long, the evidence
suggests that the SARS outbreak not only spurred behavioral
change among Taiwanese citizens [32] but also prompted
government officials to reform the infectious disease surveillance
system [33] as well as policies for hospital management [34] and
infection control [35] in Taiwan. A notable, quantifiable change
that occurred following the SARS outbreak was the peaking of
Taiwan’s elderly influenza vaccine coverage rate at 68.4% in 2003–
2004. Vaccination rates significantly rose from a mean of 31.8%
before2003–2004toa mean of55.3%during2004–2007 (p=0.08).
These changes, in combination with increasing awareness of
infectious diseases among physicians, may have contributed to the
sustained post-SARS effect that we propose had a significant impact
on Taiwan’s elderly P&I mortality rates. Three studies in Taiwan
[36], in Wuhan City of Hubei Province in mainland China [30] and
in Hong Kong [31] support the claim that public health efforts were
sustained after the SARS epidemic. Interestingly, influenza-
associated mortalities in Taiwan, southern China and Hong Kong
in the post-SARS period were all lower than in the pre-SARS
period(personalcommunicationintheMarch15–19,2010MISMS
Oceania Regional Influenza Meeting and Workshop in Melbourne,
Australia). Moreover, many public health measures taken in
response to SARS–including advising sick students to stay at home,
teaching coughing etiquette, providing hand-cleaning facilities in
front of elevators and at building entrances, closing classes if more
than three influenza-like illnesses occur in one class, and vaccinating
high-risk populations—all had been applied during the 2009
influenza H1N1 pandemic. The effectiveness of these public health
efforts is supported by the lower total number of P&I mortalities
observed during the 2009–2010 winter season (ending February 26,
2010) than in previous years [37]. In addition, we found that people
had a greater understanding of health protection measures during
the 2009–10 pandemic influenza in SARS-affected areas/countries
such as Taiwan and Hong Kong [38]. This protective effect may
have contributed to the lower numbers of P&I deaths in 2009–10
compared to seasonal influenza in 2008–2009 and to the reduction
in total laboratory-confirmed pandemic influenza H1N1 deaths in
Taiwan (42 deaths from July 1, 2009 to May 8, 2010)) and Hong
Kong (80 deaths from July 17, 2009 to April 15, 2010) [39].
This study has five major limitations. First, Taiwan’s monthly
influenza virus isolation rates prior to 1999 were not comprehen-
sive. Second, weekly and monthly matching statuses were not
available. Third, the benefit of vaccination may be underestimated
because older elderly populations are at higher risk of developing
severe complications and deaths [40]. Fourth, the unknown
temporality of vaccinations and the presence of many possible
uncontrolled confounders (such as variations in age-specific attack
rates, prior accumulated immunity, socioeconomic conditions,
nutrition factors, public health efforts, and viral characteristics of
individual influenza viruses including infectivity, pathogenicity,
transmissibility and virulence) could not be fully accounted for in
this retrospective ecological study. Causal effects cannot be
determined with certainty from observational studies comparing
these groups (e.g., vaccine-matched versus vaccine-mismatched
groups or pre-SARS versus post-SARS groups in this study).
Additionally, uncontrolled confounders at the individual level are
a major limitation of an ecological study design. Fifth, accounting
for epitope variations in A (H3N2) viruses will require more amino
acid sequencing and serological data of the HA1 over the course of
several years. Enhanced virological surveillance in Asia, where
mostly past pandemic influenza viruses have originated [7,41], is
urgently needed because most new wild-type influenza virus strains
have appeared much earlier in Taiwan and South-East Asia [42]
than in WHO-recommended vaccine strains [8,22]. Furthermore,
viral changes and co-circulating subtypes/types have been
documented in the later periods of influenza epidemics [43].
Antigenic distance between the vaccine and circulating strains can
be best measured by serologically testing simultaneously for
vaccine strains and 20–30 local influenza isolates obtained from
various time intervals of the same year (in which excess influenza-
associated mortality is identified). Unfortunately, we did not have
enough monthly retrospective samples to incorporate serological
results into the model during the study period. The major
limitation of this study was a lack of long-term data that prevents
us from drawing definitive conclusions. However, we have
illustrated possible associations between the observed reduction
in P&I mortality and vaccine match on the one hand, and the
post-SARS effect on the other hand. Our model is sufficiently
flexible to apply to different scenarios in various countries. For
minimizing a country’s/global influenza disease burden, further
studies will be required to validate the interpretations of our results
that we have suggested. International collaboration on an
integrated clinical, epidemiological, and virological/serological
influenza surveillance system will be necessary to monitor for
potential increases in clinical severity as well as viral sequence and
antigenic changes in any parts of the world.
This study points to a number of possible directions for
improving influenza vaccination policy and provides a means for
public health officials to monitor for possible occurrences of
vaccine-mismatched influenza viruses at the population level.
Moreover, our study attempts to lay a foundation for a molecular
explanation of influenza-associated deaths that integrates macro-
level mortality data with micro-level amino acid sequence identity
percentage. We hope that our findings can prompt the discovery
of better and more effective mechanisms for selecting strains for
future serological testing. In the future, we hope to collect more
data domestically and internationally in order to reevaluate and
refine our recommendations. Public health professionals in SARS-
affected countries can also examine the post-SARS impact and
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concerted effort to obtain more evidence can bring the
international community closer to devising more effective
guidelines for the global control of next pandemic influenza.
Future research efforts should include: (1) weekly/daily monitoring
of influenza viral sequences, antigenic changes of the HA [44], and
excess influenza-associated mortality; (2) an evaluation of vaccine
efficacy through measurement of antigenic distances [45,46], and
B- and T-cell epitopes [47]; and (3) improvements in influenza
vaccines through enhancement of innate immunity [48,49,50].
Supporting Information
Figure S1 Monthly isolation rates of human influenza viruses [A
(H1N1), A (H3N2), and B] in Taiwan from October 1999 to
September 2007.
Found at: doi:10.1371/journal.pone.0011317.s001 (0.04 MB
DOC)
Figure S2 Observed and estimated influenza-associated deaths
in Taiwan from October 1999 to September 2007.
Found at: doi:10.1371/journal.pone.0011317.s002 (0.15 MB
DOC)
Figure S3 (A). Temporal trend in influenza vaccine coverage
rates and elderly pneumonia and influenza mortality (crude versus
age-adjusted mortality rates) in Taiwan, from 1998–1999 to 2006–
2007 influenza seasons. (B). Pneumonia and influenza mortality
among three elderly age groups in Taiwan, from 1998–1999 to
2006–2007 influenza seasons.
Found at: doi:10.1371/journal.pone.0011317.s003 (0.03 MB
DOC)
Figure S4 Phylogenetic analysis of amino acid sequences of
HA1 proteins. Phylogenetic analysis of amino acid sequences of
HA1 proteins in 64 Taiwanese human H3N2 viruses isolated from
1996 to 2008 and the three influenza vaccine virus strains
recommended by WHO [A/Sydney/5/1997 (H3N2), A/Mos-
cow/10/1999 (H3N2), and A/Fujian/411/2002 (H3N2)].
Found at: doi:10.1371/journal.pone.0011317.s004 (0.14 MB
DOC)
Figure S5 The 3D structure of the three newly undefined
epitopes of human influenza A (H3N2) viruses during the three
vaccine-mismatched influenza seasons in Taiwan, 1999–2007.
Epitopes of A–E and newly undefined epitope regions were
marked with different colors [Epitope A in red, Epitope B in
yellow, Epitope C in purple, Epitope D in light blue, Epitope E in
light brown, Old Undefined Epitope (documented in literature) in
orange, Newly Undefined Epitope that we identified from this
study in white shown by pink arrow].
Found at: doi:10.1371/journal.pone.0011317.s005 (0.35 MB
DOC)
Table S1 Yearly comparisons between vaccine strains and
circulating wild-type dominant strains of human influenza A/
H3N2 and A/H1N1 viruses isolated in Taiwan from the 1999–
2000 to 2006–2007 epidemic seasons.
Found at: doi:10.1371/journal.pone.0011317.s006 (0.04 MB
DOC)
Table S2 Comparison between elderly excess pneumonia &
influenza (P&I) deaths and mortality rates in Taiwan in winter and
summer influenza Seasons from 1999–2000 to 2006–2007.
Found at: doi:10.1371/journal.pone.0011317.s007 (0.04 MB
DOC)
Table S3 Number of amino acid variations at A, B, C, D, E and
Old/New Undefined Epitopes between co-/circulating and
vaccine strains of human influenza A (H3N2) viruses in the 3
H3N2 vaccine-mismatched years in Taiwan.
Found at: doi:10.1371/journal.pone.0011317.s008 (0.03 MB
DOC)
Table S4 Amino acid variants at the specific sites that literature
documented and Old/New Undefined Epitopes between vaccine
and dominant circulating strains of A (H3N2) in Taiwan in the
influenza seasons of 1999–2000, 2003–04 and 2004–05.
Found at: doi:10.1371/journal.pone.0011317.s009 (0.04 MB
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